Exploring concurrent validity of the CLN2 Clinical Rating Scale: Comparison to PedsQL using cerliponase alfa clinical trial data
PLOS ONE · 2024
DOI: 10.1371/journal.pone.0302382 ↗Kurz gefasst
Klinische Studie (Phase II) in der Zeitschrift PLOS ONE, 2024. Verfasst von Nicola Specchio und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neuroscience, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy. Hauptthemen laut MEDLINE: Quality of Life, Neuronal Ceroid-Lipofuscinoses. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: biomarin pharmaceutical.
Abstract (Originalsprache)
Background
The CLN2 Clinical Rating Scale evaluates disease progression in CLN2 disease, an ultra-rare, neurodegenerative disorder with late infantile onset. To validate the Clinical Rating Scale, a comparison with the Pediatric Quality of Life Inventory (PedsQL) was conducted utilising clinical trial data investigating cerliponase alfa use in CLN2 disease.
Methods
Linear regression and mixed effects models were used to investigate the relationship between the Clinical Rating Scale and PedsQL using open-label, single-arm, phase 1/2 (NCT01907087) and ongoing extension study (NCT02485899) data of 23 children with CLN2 disease treated with cerliponase alfa for ≥96 weeks.
Results
Correlations between the four Clinical Rating Scale domains were low. Linear mixed effects analyses showed significant correlation between PedsQL and Clinical Rating Scale (Total score or motor-language [ML] score adjusted p-values
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Neuroscience, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy.
- NIHR Biomedical Research Centre, UCL Great Ormond Street Institute of Child Health, London, United Kingdom.
- Department of Pediatric Neurology, Nationwide Children's Hospital, Columbus, Ohio, United States of America.
- BioMarin Europe Ltd, London, United Kingdom.
- Costello Medical, Manchester, United Kingdom.
- Costello Medical, Cambridge, United Kingdom.
ORCID-Profile: Nicola Specchio
Förderung
- biomarin pharmaceutical
Zitieren
APA
Specchio, N., Gissen, P., de Los Reyes, E., Olaye, A., Camp, C., Curteis, T., Griffiths, A., Butt, T., Cohen-Pfeffer, J., Slasor, P., Sisic, Z., Jain, M., & Schulz, A. (2024). Exploring concurrent validity of the CLN2 Clinical Rating Scale: Comparison to PedsQL using cerliponase alfa clinical trial data. PLOS ONE. https://doi.org/10.1371/journal.pone.0302382
Vancouver
Specchio N, Gissen P, de Los Reyes E, Olaye A, Camp C, Curteis T, et al. Exploring concurrent validity of the CLN2 Clinical Rating Scale: Comparison to PedsQL using cerliponase alfa clinical trial data. PLOS ONE. 2024. doi:10.1371/journal.pone.0302382
BibTeX
@article{Specchio2024,
author = {Specchio, Nicola and Gissen, Paul and de Los Reyes, Emily and Olaye, Andrew and Camp, Charlotte and Curteis, Tristan and Griffiths, Annabel and Butt, Thomas and Cohen-Pfeffer, Jessica and Slasor, Peter and Sisic, Zlatko and Jain, Mohit and Schulz, Angela},
title = {Exploring concurrent validity of the CLN2 Clinical Rating Scale: Comparison to PedsQL using cerliponase alfa clinical trial data},
journal = {PLOS ONE},
year = {2024},
doi = {10.1371/journal.pone.0302382}
}
EUVIMED